One-Time Gene-Editing Therapy CTX310: A New Frontier in Lipid Management
One-Time Gene-Editing Therapy CTX310: A New Frontier in Lipid Management
Source: AHA Scientific Sessions 2025 — Published in NEJM (2025)
A Revolutionary, First-of-its-kind (first-in-human study) presented at the American Heart Association Scientific Sessions 2025 and simultaneously published in the New England Journal of Medicine (NEJM, 2025) has revealed unprecedented results for CTX310, A potentially once-in-a-lifetime, one-and-done intravenous gene-editing therapy.
The therapy permanently switches off the gene ANGPTL3 (Angiopoietin-like protein 3)—a key regulator of triglycerides and LDL cholesterol.
Keynotes:
1. Study Overview
1. The therapy CTX310 uses in vivo gene editing to disable the ANGPTL3 gene. (ANGPTL3 = main liver gene controlling triglycerides + LDL).
2. 15 high-risk patients with severe lipid disorders received one single IV dose.
3. The study was funded by CRISPR Therapeutics and conducted at leading U.S. centers.
2. Key Findings (Unprecedented Results)
1. LDL cholesterol dropped sharply within 2 weeks, sustained for ≥ 60 days.
2. Triglycerides also decreased significantly during the same period.
3. Every single patient in the trial experienced measurable lipid reduction.
4. Lead author Dr. Luke Laffin described the results as: “truly unprecedented.”
5. Senior author Dr. Steven Nissen emphasized the importance of “one-and-done” therapy for lifelong lipid disorders.
3. Mechanism of Action :
1. Statins → Block cholesterol synthesis → Daily use for life.
2. PCSK9 inhibitors (Repatha, Praluent) → Prevent LDL-receptor degradation → Injections every 2–4 weeks.
3. Inclisiran → Silences PCSK9 mRNA → Twice-yearly injection.
4. CTX310 → Gene-editing to switch off ANGPTL3 (gene responsible for regulating LDL & triglycerides) →
Potentially permanent effect after a single dose.
4. Dosing Pattern Comparison
1. Statins – Oral, daily for life.
2. PCSK9 mAbs – Injection every 2–4 weeks.
3. Inclisiran – Every 6 months.
4. CTX310 – One IV infusion only (conceptually once per lifetime if long-term safety is confirmed).
5.
⸻
Strength of Lipid Reduction
1. Statins:
LDL ↓ ~50–60% (baseline therapy).
2. PCSK9 inhibitors (Repatha, Praluent):
LDL ↓ 50–60% additional beyond statins — strongest potency available but limited by high cost and frequent injections.
3. Inclisiran (Leqvio):
LDL ↓ ~50% total — adds ~10–15% beyond statins; major advantage is excellent adherence due to twice-yearly dosing.
4. Ezetimibe:
LDL ↓ 18–22% — safe, inexpensive, and provides a moderate add-on effect.
5. Bempedoic Acid:
LDL ↓ 15–20% — best option for statin intolerance because it is activated in the liver only (not the muscles); oral and well tolerated.
6. CTX310 (Phase 1):
• Strong reductions in LDL and triglycerides by Week 2.
• Sustained for ≥ 60 days.
• LDL ↓ ~50% at the highest dose.
• Triglycerides ↓ ~55% at the highest dose.
• Long-term durability still under investigation.
6. Adherence Advantages
1. Statins: Poor adherence — 50% stop within one year.
2. PCSK9: Adherence depends on insurance and frequent injections.
3. Inclisiran: Better adherence (twice yearly).
4. CTX310:
• Perfect theoretical adherence (one treatment only)
• Solves decades-long adherence problems in lipid management.
7. Safety Profile
1. Generally safe in early data.
2. Study reported: 2 serious adverse events + 3 infusion-related reactions.
8. Who Might Benefit in the Future?
1. Patients with lifelong severe lipid disorders.
2. Very high-risk ASCVD patients uncontrolled on maximum therapy.
3. Patients who cannot tolerate statins.
4. Patients with major adherence issues where one-time therapy is ideal.
Conclusion
CTX310 represents the first real possibility of a single-dose, lifetime lipid treatment, targeting ANGPTL3 through permanent gene editing.
If confirmed in larger trials, this therapy may reshape cardiovascular prevention and offer a transformative option for patients with severe lifelong dyslipidemia.
